Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Risa Motai
Michi Sawabe
Shigenori Kadowaki
Eiichi Sasaki
Daisuke Nishikawa
Hidenori Suzuki
Shintaro Beppu
Hoshino Terada
Nobuhiro Hanai
机构：
[1] Aichi Cancer Center,Department of Head and Neck Surgery
[2] Aichi Cancer Center,Department of Medical Oncology
[3] Aichi Cancer Center,Department of Pathology and Molecular Diagnostics
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Head and neck cancer; EXTREME; Paclitaxel; Cetuximab; Platinum-refractory; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1188 / 1195
页数：7
相关论文
共 50 条
  • [21] Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Specenier, Pol
    Rasschaert, Marika
    Vroman, Philippe
    Van den Brande, Jan
    Dyck, Joke
    Schrijvers, Dirk
    Huizing, Manon T.
    Vermorken, Jan B.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (05): : 472 - 477
  • [22] Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Hitt, R
    Amador, ML
    Quintela-Fandino, M
    Jimeno, A
    del Val, O
    Hernando, S
    Cortes-Funes, H
    CANCER, 2006, 106 (01) : 106 - 111
  • [23] Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Specenier, P.
    Rasschaert, M.
    Vroman, Ph
    ORAL ONCOLOGY, 2009, : 93 - 93
  • [24] Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas
    Locke, Margaret
    Kohn, Nina
    Seetharamu, Nagashree
    CLINICAL OTOLARYNGOLOGY, 2023, 48 (06) : 915 - 919
  • [25] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [26] Quality of life of elderly patients receiving weekly carboplatin and paclitaxel chemotherapy plus cetuximab first line for metastatic squamous cell carcinoma of the head and neck
    Lugini, A.
    Rossi, R.
    Pace, R.
    Rauco, A.
    Santarelli, M.
    Capparella, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S752 - S752
  • [27] Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Kodama, Hiroyuki
    Kadowaki, Shigenori
    Ishizuka, Yasunobu
    Wakabayashi, Munehiro
    Sakakida, Tomoki
    Honda, Kazunori
    Masuishi, Toshiki
    Narita, Yukiya
    Taniguchi, Hiroya
    Ando, Masashi
    Kishikawa, Toshihiro
    Terada, Hoshino
    Beppu, Shintaro
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Hanai, Nobuhiro
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 480 - 488
  • [28] Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Bhatia, Aarti K.
    Mehra, Ranee
    Khan, Saad A.
    Egleston, Brian L.
    Alpaugh, R. Katherine
    Lango, Miriam
    Ridge, John A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
    Ye D.
    Liang X.
    Chen X.
    Li Y.
    Scientific Reports, 14 (1)
  • [30] Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Seront, E.
    Schmitz, S.
    Rottey, S.
    Henry, S.
    Lonchay, C.
    van Caloen, G.
    Gilain, A.
    Machiels, J-P.
    ANNALS OF ONCOLOGY, 2016, 27
12345